Terms: = Liver cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
1175 results:
1. Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.
Zeng D; Yu C; Chen S; Zou L; Chen J; Xu L
World J Surg Oncol; 2024 Apr; 22(1):93. PubMed ID: 38605359
[TBL] [Abstract] [Full Text] [Related]
2. Challenges in Diagnosis and treatment of Male Hypogonadism.
Purnamasari D
Acta Med Indones; 2024 Jan; 56(1):1-2. PubMed ID: 38561883
[TBL] [Abstract] [Full Text] [Related]
3. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract] [Full Text] [Related]
4. Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells.
Chaisupasakul P; Pekthong D; Wangteeraprasert A; Kaewkong W; Somran J; Kaewpaeng N; Parhira S; Srisawang P
PLoS One; 2024; 19(3):e0300051. PubMed ID: 38527038
[TBL] [Abstract] [Full Text] [Related]
5. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
Ji J; Zhang Z; Hou Z; Qiu G; Mi S; Jin Z; Huang J
Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102313. PubMed ID: 38453011
[TBL] [Abstract] [Full Text] [Related]
7. Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level.
Hwang H; Kim JH; Ko E; Kim JY; Ko HK; Gwon DI; Shin JH; Kim GH; Chu HH
Br J Radiol; 2024 May; 97(1157):1038-1043. PubMed ID: 38445658
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract] [Full Text] [Related]
9. Risk factors associated with hepatitis D virus infection and preventive strategies in Mongolia.
Su CW; Ochirkhuree B; Namdag B; Badamnachin B; Ganbold S; Gidaagaya S; Ganbold A; Yang SS; Duger D; Wu JC
J Chin Med Assoc; 2024 May; 87(5):480-487. PubMed ID: 38417133
[TBL] [Abstract] [Full Text] [Related]
10. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
[TBL] [Abstract] [Full Text] [Related]
11. Adherence and impact of an oral nutritional supplement enriched in leucine, EVOO, EPA and DHA, and beta-glucans on the coverage of energy and protein requirements in patients with cancer and malnutrition: Alisenoc study.
Milla SP; Luna PPG; Casariego AV; González FV; Folgueras TM; Jáuregui OI; Rey SG; Fernández AC; Plaza BL; Quintana TC; de Luis Román DA
Nutrition; 2024 Apr; 120():112355. PubMed ID: 38341907
[TBL] [Abstract] [Full Text] [Related]
12. FOXS1 is increased in liver fibrosis and regulates TGFβ responsiveness and proliferation pathways in human hepatic stellate cells.
Bates EA; Kipp ZA; Lee WH; Martinez GJ; Weaver L; Becker KN; Pauss SN; Creeden JF; Anspach GB; Helsley RN; Xu M; Bruno MEC; Starr ME; Hinds TD
J Biol Chem; 2024 Mar; 300(3):105691. PubMed ID: 38280429
[TBL] [Abstract] [Full Text] [Related]
13. Exploring the Potential of Montmorillonite as an Antiproliferative Nanoagent against MDA-MB-231 and MCF-7 Human Breast cancer Cells.
Sabzevari AG; Sabahi H; Nikbakht M; Azizi M; Dianat-Moghadam H; Amoozgar Z
Cells; 2024 Jan; 13(2):. PubMed ID: 38275825
[TBL] [Abstract] [Full Text] [Related]
14. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Emiloju OE; Yin J; Koubek E; Reid JM; Borad MJ; Lou Y; Seetharam M; Edelman MJ; Sausville EA; Jiang Y; Kaseb AO; Posey JA; Davis SL; Gores GJ; Roberts LR; Takebe N; Schwartz GK; Hendrickson AEW; Kaufmann SH; Adjei AA; Hubbard JM; Costello BA
Invest New Drugs; 2024 Feb; 42(1):127-135. PubMed ID: 38270822
[TBL] [Abstract] [Full Text] [Related]
15. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract] [Full Text] [Related]
16. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in treatment-Naïve Patients with Chronic Hepatitis B.
Kim TH; Kim JH; Yim HJ; Seo YS; Yim SY; Lee YS; Jung YK; Yeon JE; Um SH; Byun KS
Gut Liver; 2024 Mar; 18(2):305-315. PubMed ID: 38213189
[TBL] [Abstract] [Full Text] [Related]
17. Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M; Hikita H; Kazuki M; Tahata Y; Shinkai K; Doi A; Ohkawa K; Miyazaki M; Ishida H; Matsumoto K; Nozaki Y; Yakushijin T; Sakamori R; Kaneko A; Iio S; Nawa T; Kakita N; Morishita N; Hiramatsu N; Usui T; Imanaka K; Doi Y; Sakakibara M; Yoshida Y; Oze T; Kodama T; Tatsumi T; Takehara T
PLoS One; 2024; 19(1):e0294590. PubMed ID: 38165900
[TBL] [Abstract] [Full Text] [Related]
18. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract] [Full Text] [Related]
19. Polysaccharides from Spirulina platensis (PSP): promising biostimulants for the green synthesis of silver nanoparticles and their potential application in the treatment of cancer tumors.
Al-Badwy AH; Khalil AM; Bashal AH; Kebeish R
Microb Cell Fact; 2023 Dec; 22(1):247. PubMed ID: 38053190
[TBL] [Abstract] [Full Text] [Related]
20. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.
Melisi D; Zecchetto C; Merz V; Malleo G; Landoni L; Quinzii A; Casalino S; Fazzini F; Gaule M; Pesoni C; Casetti L; Esposito A; Marchegiani G; Piazzola C; D'Onofrio M; de Robertis R; Gabbrielli A; Bernardoni L; Crino SF; Pietrobono S; Luchini C; Aliberti C; Martignoni G; Milleri S; Butturini G; Scarpa A; Salvia R; Bassi C
Eur J Cancer; 2024 Jan; 196():113430. PubMed ID: 37995598
[TBL] [Abstract] [Full Text] [Related]
[Next]
